Enviaments recents

Encorafenib plus cetuximab for the treatment of BRAF-V600E-mutated metastatic colorectal cancer

Ros Montañá, Fco. Javier; Baraibar Argota, Iosune; Salva Ballabrera, Francesc; Tabernero Caturla, Josep; Elez Fernandez, Mª Elena; Saoudi Gonzalez, Nadia (Data de publicació: 2022-10-26)

BRAF mutation; Cetuximab; Colorectal cancer

A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer

Pascual, Tomás; Martin, Miguel; Fernández-Martínez, Aranzazu; Alba, Emilio; Rodríguez-Lescure, Álvaro; Cortés Castan, Javier; Paré, Laia (Data de publicació: 2021-03-19)

No luminal; Subtipus intrínsec; Càncer de mama

PCIG: a web-based application to explore immune–genomics interactions across cancer types

Franch-Exposito, Sebastia; Lahoz, Sara; Esteban-Fabró, Roger; Bassaganyas, Laia; Camps, Jordi; Dienstmann, Rodrigo; Pedrola Gómez, Anna (Data de publicació: 2022-07-20)

Cancer; Application; Genomic alterations

Plain language summary of the CheckMate 816 study results: nivolumab plus chemotherapy given before surgery for non–small-cell lung cancer

Forde, Patrick; Spicer, Jonathan; provencio, mariano; Mitsudomi, Tetsuya; Awad, Mark; Lu, Shun; FELIP, ENRIQUETA (Data de publicació: 2023-08-02)

Immunotherapy; Neoadjuvant treatment; Presurgery treatment

Immune predictors of response to immune checkpoint inhibitors in mismatch repair-deficient endometrial cancer

ZENG, Qinghe; genestie, catherine; Rouleau, Etienne; de Bruyn, Marco; Grau Bejar, Juan Francisco; Yaniz-Galende, Elisa; OAKNIN, ANA (Data de publicació: 2024-07-05)

Biomarcador; Inhibidores del punto de control inmunitario; Microambiente tumoral

Clinical and genetic factors associated with tumor response to neoadjuvant (chemo)radiotherapy, survival and recurrence risk in rectal cancer

Hammarström, Klara; Nunes, Luis; Mathot, Lucy; Lundin, Emma; Korsavidou Hult, Nafsika Dimitra; Mezheyeuski, Artur (Data de publicació: 2024-05-22)

Neoadjuvant therapy; Prognosis; Rectal cancer

Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients

Lozano, Rebeca; Lorente, David; Aragon, Isabel M.; Romero-Laorden, Nuria; Nombela, Paz; Mateo Valderrama, Joaquim (Data de publicació: 2022-03-01)

Biomarcadores; Células tumorales circulantes; Docetaxel

RAD51 as a biomarker for homologous recombination deficiency in high-grade serous ovarian carcinoma: robustness and interobserver variability of the RAD51 test

Kramer, Claire; Yaniz-Galende, Elisa; Pellegrino, Benedetta; ter Haar, Natalja; Llop-Guevara, Alba; Herencia Ropero, Andrea; Serra, Violeta (Data de publicació: 2023-10-16)

Biomarker; High-hrade serous ovarian carcinoma; Homologous recombination deficiency

Pharmacokinetic Analysis of Omomyc Shows Lasting Structural Integrity and Long Terminal Half-Life in Tumor Tissue

Martínez Martín, Sandra; Castillo Cano, Virginia; Massó Vallés, Daniel; López-Estévez, Sergio; Thabussot, Hugo; Beaulieu, Marie-Eve; Soucek, Laura; Foradada Felip, Laia; Kaur, Jastrinjan; Serrano del Pozo, Erika (Data de publicació: 2023-03-16)

Omomyc; Mass spectrometry; Protein therapeutics

Predictive Role of CD36 Expression in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Trastuzumab

Ligorio, Francesca; Di Cosimo, Serena; verderio, paolo; ciniselli, chiara maura; Pizzamiglio, Sara; Castagnoli, Lorenzo; Nuciforo, Paolo (Data de publicació: 2023-05-17)

CD36 expression; Breast cancer; Neoadjuvant trastuzumab

MYC: there is more to it than cancer

Zacarias Fluck, Mariano F; Soucek, Laura; Whitfield, Jonathan (Data de publicació: 2024-03-26)

MYC; Non-oncological diseases; Transcription factor

Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines

Ciardiello, Davide; Belli, Valentina; Matrone, Nunzia; Cardone, Claudia; Martini, Giulia; Vitiello, Pietro Paolo (Data de publicació: 2019-03-04)

Colorectal cancer; Epidermal growth factor receptor (EGFR); MAPK pathway

Reducing MYC's transcriptional footprint unveils a good prognostic gene signature in melanoma

Zacarias Fluck, Mariano F; Massó-Vallés, Daniel; Giuntini, Fabio; González-Larreategui, Íñigo; Kaur, Jastrinjan; Casacuberta-Serra, Sílvia; Jauset González, Antoni; Martínez Martín, Sandra; Martín Fernández, Génesis; Serrano del Pozo, Erika; Foradada Felip, Laia; Grueso Gragera, Judit; Nonell Malezon, Lara; Whitfield, Jonathan; Beaulieu, Marie-Eve; Soucek, Laura (Data de publicació: 2023-09-26)

MYC; Omomyc; Melanoma

Trotabresib (CC-90010) in combination with adjuvant temozolomide or concomitant temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma

Vieito Villar, Maria; De Vos, Filip; Marjolein Geurts; Lorenzi, Elena; Simonelli, Matteo; Moreno, Victor (Data de publicació: 2022-12-02)

BET inhibitors; Glioblastoma; Pharmacokinetics

Advances in immune checkpoint inhibitor combination strategies for microsatellite stable colorectal cancer

Ros Montañá, Fco. Javier; Balconi, Francesca; Baraibar Argota, Iosune; Salva Ballabrera, Francesc; Tabernero Caturla, Josep; Elez Fernandez, Mª Elena; Saoudi Gonzalez, Nadia (Data de publicació: 2023-03-16)

Colorectal cancer; Microsatellite stable; Tyrosine kinase inhibitors

ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group

Pascual, Javier; Attard, Gerhardt; Bidard, François-Clement; Diehn, Maximilian; Seoane Suarez, Joan; Curigliano, Giuseppe; De Mattos-Arruda, Leticia (Data de publicació: 2023-04-17)

Circulating tumour DNA (ctDNA); Liquid biopsy; Precision medicine

Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohorts

Strand, Siri H; Rivero-Gutierrez, Belen; Houlahan, Kathleen; Seoane Fernández, Jose Antonio; King, Lorraine M.; Risom, Tyler (Data de publicació: 2022-12-29)

Ductal carcinoma in situ; Tumor microenvironment; Whole genome sequencing

Early Diagnosis of Oral Cancer and Lesions in Fanconi Anemia Patients: A Prospective and Longitudinal Study Using Saliva and Plasma

Carrasco López, Estela; Del Marro, Sonia; Suñol, Anna; Peral, Jorge; Ortiz, Jessica; Balmaña Gelpí, Judith; Errazquin, Ricardo (Data de publicació: 2023-04-04)

Fanconi anemia; Cancer gene; Saliva

Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study

Garralda Cabanas, Elena; Eskens, Ferry; Gil-Martin, Marta; Yen, Chia-Jui; Simonelli, Matteo; Santoro, Armando (Data de publicació: 2023-01-11)

Atezolizumab; Isatuximab; Solid tumors

Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis

Carey, Lisa; Loirat, Delphine; Dieras, Veronique; Cortés Castan, Javier; Bardia, Aditya; Punie, Kevin; Dalenc, Florence (Data de publicació: 2022-09-09)

Breast cancer; Second-line treatment

Articles científics - VHIO: Enviaments recents

Encorafenib plus cetuximab for the treatment of BRAF-V600E-mutated metastatic colorectal cancer ﻿

A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer ﻿

PCIG: a web-based application to explore immune–genomics interactions across cancer types ﻿

Plain language summary of the CheckMate 816 study results: nivolumab plus chemotherapy given before surgery for non–small-cell lung cancer ﻿

Immune predictors of response to immune checkpoint inhibitors in mismatch repair-deficient endometrial cancer ﻿

Clinical and genetic factors associated with tumor response to neoadjuvant (chemo)radiotherapy, survival and recurrence risk in rectal cancer ﻿

Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients ﻿

RAD51 as a biomarker for homologous recombination deficiency in high-grade serous ovarian carcinoma: robustness and interobserver variability of the RAD51 test ﻿

Pharmacokinetic Analysis of Omomyc Shows Lasting Structural Integrity and Long Terminal Half-Life in Tumor Tissue ﻿

Predictive Role of CD36 Expression in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Trastuzumab ﻿

MYC: there is more to it than cancer ﻿

Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines ﻿

Reducing MYC's transcriptional footprint unveils a good prognostic gene signature in melanoma ﻿

Trotabresib (CC-90010) in combination with adjuvant temozolomide or concomitant temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma ﻿

Advances in immune checkpoint inhibitor combination strategies for microsatellite stable colorectal cancer ﻿

ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group ﻿

Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohorts ﻿

Early Diagnosis of Oral Cancer and Lesions in Fanconi Anemia Patients: A Prospective and Longitudinal Study Using Saliva and Plasma ﻿

Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study ﻿

Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis ﻿